Compare Carvana Co (CVNA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Neurocrine Biosciences Inc — how do they compare? Carvana Co trades at $63.73 (market cap $69.55B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Carvana Co is far larger — about 4.8× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Neurocrine Biosciences Inc for 23 Days on average.
| CVNA | NBIX | |
|---|---|---|
Market Cap | $69.55B | $14.36B |
Volume | 7,671,750 | 1,237,180 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $185.50 |
52-Week Low | $56.27 | $123.10 |
Typical Hold Time | 28 Days | 23 Days |
Enterprise Value | $72.04B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $63.21, up 0.72% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 revenue up 52% and net income of $1.41 billion in 2025. Analyst sentiment is divided, with a consensus price target of $84.07, but technical indicators suggest near-term resistance at $64.
The outlook for CVNA hinges on sustained revenue growth and margin expansion, supported by operational improvements and capacity expansions. Key risks include high debt levels, competitive pressures, and sensitivity to interest rates. Upside potential exists if the company continues to exceed earnings expectations and expand its market share in the online used car sector.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with technical indicators showing a bearish trend despite strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.85 significantly exceeding expectations of $1.85. Revenue growth remains strong, projected to increase from $2.9B in 2025 to $3.4B in 2026, while net profit margins expanded from 16.73% to 20.91%.
Wall Street maintains strong bullish sentiment with 86% buy ratings and a $204.18 consensus price target, representing 45% upside potential. Key risks include execution challenges with the expanding product portfolio and potential pricing pressure on INGREZZA ahead of 2029 patent considerations. The technical bearish signal contrasts with fundamental strength, creating potential entry opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
